
    
      To investigate if dapagliflozin improves skeletal muscle insulin sensitivity expressed as
      corrected glucose disposal rate (cGDR) in comparison with placebo after 5-week double blind
      treatment. Insulin sensitivity will be determined using a 2-step euglycemic hyperinsulinemic
      clamp (EHC) procedure
    
  